Clearside Biomedical logo
Clearside Biomedical CLSD

Quarterly report 2025-Q3
added 11-14-2025

report update icon

Clearside Biomedical Cash Flow 2011-2026 | CLSD

Annual Cash Flow Clearside Biomedical

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-18.1 M -13.4 M -10.7 M -13.1 M -27.1 M -79.2 M -51.1 M -22.7 M - - - - -

Depreciation & Amortization

67 K 145 K 178 K 180 K 211 K 189 K 182 K 65 K 60 K 33 K - - -

Accounts Payables

2.2 M 1.05 M 941 K 2 M 1.28 M 6.87 M 5.38 M 2.59 M - - - - -

Accounts Receivables

170 K - 10 M - - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Clearside Biomedical

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -5.83 M - - - -7.85 M - - - -7.22 M - -7.76 M -1.57 M 3.87 M - -15.8 M -12.5 M -5.56 M - -8.68 M -6.02 M -2.8 M - -28.8 M -22.7 M -12.7 M - -54.9 M -35.2 M -15.7 M - -36 M -22.5 M - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

- - 85 K - - - 28 K - - - 15 K - 123 K 84 K 46 K - 133 K 89 K 45 K - 136 K 90 K 45 K - 160 K 107 K 53 K - 141 K 94 K 47 K - 135 K 87 K 30 K - 49 K 32 K 17 K - 45 K 31 K - - - - - - - - - - - - - - - - -

Accounts Payables

796 K 1.13 M 1.91 M 1.45 M 2.36 M 1.58 M - 2.2 M 1.87 M 1.89 M 1.59 M 1.05 M 1.74 M 2.64 M 1.4 M 941 K 776 K 1.22 M 2.34 M 2 M 2 M 2 M 2 M 1.28 M 1.28 M 1.28 M 1.28 M 6.87 M 6.87 M 6.87 M 6.87 M 5.38 M 5.38 M 5.38 M 5.38 M 2.59 M 2.59 M 2.59 M 2.59 M 1.47 M 1.47 M 1.47 M - - - - - - - - - - - - - - - - -

Accounts Receivables

266 K 816 K 1.54 M 507 K 788 K - - 170 K 882 K 255 K - 91 K 123 K 123 K - 10 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Clearside Biomedical, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Amgen Amgen
AMGN
$ 345.82 1.71 % $ 186 B usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 12.61 2.35 % $ 3.95 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
argenx SE argenx SE
ARGX
$ 776.24 1.41 % $ 25 B niderlandNiderland
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.35 4.64 % $ 3.1 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.44 5.51 % $ 383 M britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.85 2.39 % $ 9.26 B australiaAustralia
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.74 6.42 % $ 17.2 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 91.34 1.92 % $ 27.2 B germanyGermany
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.63 1.87 % $ 767 M britainBritain
Cabaletta Bio Cabaletta Bio
CABA
$ 3.09 0.65 % $ 310 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.07 1.32 % $ 6.68 B israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 1.94 5.43 % $ 370 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 2.92 6.18 % $ 7.62 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.68 0.6 % $ 197 M usaUSA